concept

AADC

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about AADC: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

321Connections
0Hypotheses
3Analyses
50Outgoing
50Incoming
0Experiments
3Debates

No summary available yet. View on Wiki →

No AI portrait yet

💡 Concept Info
NameAADC
Key Genes/ProteinsActin, AGING, AHR, ALOX15
Related DiseasesAADC deficiency, adrenoleukodystrophy, Aging, Als, ALS

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

Principal Pars Compacta

cell · 920 words

AADC Gene Therapy for Parkinson's Disease

therapeutic · 968 words

AADC Neurons

cell · 562 words

Pathway Diagram

graph TD
    AADC["AADC"]
    style AADC fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    AADC -->|"catalyzes"| Dopamine["Dopamine"]
    AADC -->|"catalyzes"| Tryptamine["Tryptamine"]
    AADC -->|"catalyzes"| Dopamine_Synthesis["Dopamine Synthesis"]
    AADC -->|"catalyzes"| Serotonin_Synthesis["Serotonin Synthesis"]
    AADC -->|"catalyzes"| Serotonin["Serotonin"]
    AADC -->|"substrate_of"| L_DOPA["L-DOPA"]
    AADC -->|"expressed in"| Non_dopaminergic_Neurons["/Non-dopaminergic Neurons/"]
    AADC -->|"implicated in"| neurodegeneration["neurodegeneration"]
    AADC -->|"involved_in"| dopamine{"dopamine"}
    h_7bb47d7a["h-7bb47d7a"] -->|"targets"| AADC
    TH([TH]) -->|"co_expressed_with"| AADC
    Therapeutics["Therapeutics"] -->|"references"| AADC
    Cell_Types["Cell Types"] -->|"references"| AADC
    Gene_Therapy_for_Neurodegenera["Gene Therapy for Neurodegenerative Diseases"] -->|"references"| AADC
    NURR1_Agonist_Therapy_for_Park["NURR1 Agonist Therapy for Parkinson's Disease"] -->|"references"| AADC
    Drug_Target_Landscape["Drug Target Landscape"] -->|"references"| AADC
    Tissue_Engineered_Nigrostriata["Tissue Engineered Nigrostriatal Pathway for Parkinson's Disease"] -->|"references"| AADC
    COMT_Inhibitors["COMT Inhibitors"] -->|"references"| AADC
    AAV_Vectors_in_Neurodegenerati["AAV Vectors in Neurodegenerative Disease Gene Therapy"] -->|"references"| AADC

Outgoing (197)

TargetRelationTypeStr
oxidative stress responseparticipates_inpathway0.90
THassociated_withgene0.80
neuronsassociated_withcell_type0.80
serotoninassociated_withneurotransmitter0.80
THreleasesgene0.70

Incoming (124)

SourceRelationTypeStr
h-7bb47d7atargets_genehypothesis0.90
h-7bb47d7atargetshypothesis0.80
levodopatargetsdrug0.80
levodopaassociated_withcompound0.70
levodopareleasescompound0.70

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (3)

Scientific analyses that reference this entity

Neuroinflammation resolution mechanisms and pro-resolving mediators

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.784

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

neurodegeneration | 2026-04-01 | 20 hypotheses Top: 0.888

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (3)

Multi-agent debates referencing this entity

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re

closed · Rounds: 4 · Score: 0.83 · 2026-04-06

What are the mechanisms underlying what are the mechanisms by which gut microbio

closed · Rounds: 4 · Score: 0.95 · 2026-04-01